In the Asia-Pacific region, company officials report triplling revenue during the last five years and now employing more than 250 representatives. Further short-term growth is expected to be driven by an expanded service network, as well as new product introductions. New technology rollouts in the region will include the Orsiro, the company’s hybrid drug-eluting stent technology for coronary vascular intervention, and Lumax 740 iplantable cardioverter defibrillator for patients with tachycardia heart rhythm disorder.
“Biotronik will fully leverage the accelerated development of the Asia Pacific countries to further propel the industry-leading growth trajectory that the company has maintained during previous years despite the global economic downturn,” said Werner Braun, global managing director. “Our further plans for full-scale business development in Asia-Pacific, which will be coordinated by a highly professional team based out of the new headquarters in Asia, are the latest milestone of many more to come for Biotronik and our customers in this region.”
The company's U.S. facilities are headquartered in Lake Oswego, Ore.